Methylation dependent miR-510 in prostate cancer: A novel upcoming candidate for prostate cancer

• Our studies describe that miR-510 upregulated in metastatic form of prostate cancer.
• We analyzed expressions and methylation status of miR-510 in various kinds for prostate cancer cell lines and biopsies.
• miR-510 promoter region was found to be unmethylated in tumor samples as well as in prostate cancer cell lines.
• We have seen upregulated PRDX1 in BPH samples than in tumor samples.
• miR-510 may serve as a novel candidate for the diagnosis and as a new therapeutic target for prostate cancer treatment.

Over the years, considerable progress has been achieved in the management of androgen sensitive prostate cancer. However, inadequacies in the early diagnosis and treatment of prostate cancer remain, resulting in poor treatment and ineffective control of metastatic progression. MicroRNAs (miRNAs) are well known regulatory factor for the cellular and developmental processes and it has been revealed that many miRNAs contribute the initiation and progression of various cancers including prostate cancer. In the present study we have analyzed the expression and methylation status of miR-510 in normal prostate cell line (PNT1A and HPrEC), primary prostate cancer cell line (LNCaP and VCaP), advanced prostate cancer cell lines (DU145 and MDA PCa 2b) as well as in human prostate cancer biopsies and benign prostatic hyperplasia (BPH) samples. Our studies revealed that miR-510 was up-regulated in metastatic form of prostate cancer cell lines (DU145 and MDA PCa 2b) and in human prostate cancer biopsies but no significant changes were noticed in miR-510 expression in other cell lines (LNCaP, VCaP and PNT1A) as well as in BPH samples. At the same time, miR-510 promoter region was found to be methylated in LNCaP and PNT1A cell lines, but in case of DU145, PC-3 cell lines and prostate cancer biopsies, the miR-510 promoter region was found to be unmethylated. Thus the miR-510 may serve as a novel candidate for the diagnosis and as a new therapeutic target for prostate cancer treatment.